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ABSTRACT 
Serine repeat antigen (SERA) of Plasmodium falciparum is believed to be an 
excellent candidate for the development of a malaria vaccine. In this study, a 22-kDa 
synthetic DNA fragment (SE22) from the N-terminal domain of SERA which was 
previously constructed by assembly polymerase chain reaction (PCR) was subcloned 
from the cloning vector, pCR®2.1-TOPO® into an expression vector, pPRoEX™HTa 
for its expression in BCG. Prior to this study, the SE22 gene was constructed in 
favour of mycobacterium codon usage and cloned into pCR®2.1-TOPO® to produce 
pNMN009. In order to express the protein, the SE22 gene was extracted from 
pNMN009 and subcloned into pPROEX™HTa to produce pNMN019. The expression 
of the fusion protein was induced with isopropylthiogalactoside (IPTG). The fusion 
protein was isolated and used to immunize two New Zealand white rabbits to produce 
polyclonal antibody against the candidate antigen. This antibody will be used to 
detect the expression of the synthetic SE22 gene in Mycobacterium bovis bacille 
Calmette Guerin. 
INTRODUCTION 
Malaria 
Malaria is one of the commonest diseases in the world affecting more than 200 
million people and killing more than 3 million annually (Vegupalan, 2002). World 
Health Organization (WHO) estimates that approximately 40o/o of the world's 
population, mostly those living in the world's poorest countries especially in tropical 
and subtropical part of the world, is at risk of malaria. Countries without the 
administrative, financial and human resources necessary for disease control usually 
have high number of case fatalities. It is a major public health problem and should not 
be overlooked. 
Etiology 
Malaria is caused by a parasite known as Plasmodium and is transmitted by the 
Anopheles mosquito. Plasmodium is a small, single-cell organism (protozoan), which 
lives as a parasite in various animal hosts including man and a specific species of 
mosquito (Anopheles) (Easmon, 2002). 
There are four different species of malaria parasite that infect humans namely 
Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale and Plasmodium 
malariae. P. falciparum is the cause of malignant malaria and by far the most 
important plasmodium parasite in Africa. On the other hand, P. vivax, P. ova/e and P. 
malariae cause benign types of malaria. 
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The disease is passed on when the mosquito bites a person who has the 
parasite in their blood. Development of parasites takes place in the intestine and 
salivary glands of the mosquito and can later be passed to another person the next 
time the mosquito takes a meal. Apart from that, malaria can also be passed on 
through blood transfusion and needle sharing . 
Clinical features 
Malaria begins as a flu-like illness. Normally it takes 10 to 15 days before the first 
symptoms appear. Typically, malaria causes fever, chills, headache, vomiting and 
without intervention, the disease can be fatal. Anemia also arises from the 
destruction of erythrocytes. 
A typical attack of malaria begins with a feeling of intense cold as the 
hypothalamus is activated and body temperature rises rapidly to 41 °C (Roberts and 
Janovy, 1996). The victim will shiver and teeth chattering can take place. Nausea and 
vomiting are common. An hour later. hot stage begins with headache and intense 
heat. This is followed by the delirium stage, which may last for a few hours. 
Perspiration marks the end of the hot stage. 
Anemia occurs when erythrocytes are destroyed and there is insufficient 
replacement. Huge quantities of erythrocyte destruction leads to increase in blood 
bilirubin , which might result in jaundice. 
Falciparum malaria may cause some complications such as celebral malaria, 
pulmonary edema and black-water fever (Roberts and Janovy, 1996). 
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Control and prevention 
Highlighting the seriousness of the disease. treatment as well as prevention is 
important. Throughout the world , use of insecticides to kill disease-carrying mosquito 
is favored. Insecticide spraying may be the most satisfying means of control but lack 
of financial and human resources prevent thorough destruction of the mosquito and 
its breeding habitat. 
Prophylactic drug treatment for travelers is another method to prevent 
transmission of malaria . A number of drugs are used for this purpose such as 
quinine, mefloquine, proguanil, tetracycline and pyrimethamine. Due to multidrug 
resistance in various strains of Plasmodium, the drugs no longer provide the 
necessary protection . Therefore. the construction of a vaccine would help 
complement the control of this disease. 
Life cycle 
Two types of hosts are required for the life cycle of Plasmodium to be completed 
(Figure 1 ). The invertebrate host (mosquito) is where sexual reproduction takes place 
and the vertebrate host (e.g. human) is where asexual reproduct ion occurs. 
When an infected mosquito takes a blood meal , sporozoites are injected into 
the bloodstream from the mosquito's salivary glands. Within an hour, the sporozoites 
travel within the blood to the liver and enter the liver cells . In the liver some of the 
sporozoites undergo asexual multiplication and become thousands of merozoites. 
The infected liver cells begin to burst releasing the merozoites into the peripheral 
circu lation and these merozoites are taken up by the erythrocytes. Some of these 
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turn into trophozoites, which split again to form schizonts. Schizonts burst the 
erythrocytes releasing the merozoites. The trophozoites that are left over during 
division can develop into the sexual form, the gametocytes, which can be taken up by 
a mosquito and start another cycle (Easmon, 2003). 
In mosquitoes 
.. 
~ In humans 
Figure 1: Life cycle of P. falciparum (Forsdyke, 2003) 
Serine repeat antigen (SERA) 
The serine repeat antigen (SERA) of P. falciparum is an asexual eryhtrocyte-stage 
antigen. Upon schizont rupture, SERA is processed into a 47 -kDa N-terminal (SE47), 
a 50-kDa central (SE50), an 18-kDa C-terminal (SE18) and a 6-kDa domain (Figure 
2) (Debrabant et a/. , 1992). The covalently associated N- and C-terminal fragments 
appear to be associated with the merozoite surface, whereas the central 50-kDa and 
6-kDa species are shed upon schizont rupture (Pang et a/. , 1999) The overall 
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structure of SERA is remarkably conserved; nearly all nucleotide replacements are 
found in exon II of the gene, which corresponds approximately to the 47-kDa domain 
of the protein (Horii eta/. , 1988; Bzik eta/., 1988; Li eta/., 1989; Knapp eta/., 1989; 
Knapp eta/. , 199.1; Fox and Bzik, 1994; Morimatsu eta/. , 1994). Exon II comprises 
two repetitive domains, the octamer repeats (OR) and the serine repeats (SR). 
Chromosome 2 SERA locus MSP2 
\ I I - ·--· ·- ···· -- - -- . __ -~fl~l- ... 1_~_1 I I 
._ ------ ... -----···:..___ ------ ----------
.. 
-
.--- ----- -.-...---
---· 
~------
Signal sequence 47 kDa fragment 56 kDa fragment 18 kDa fragment 
I . I · I I SERA Gene 
.. 
Octamer repeat region Serine repeat region 
Figure 2: Schematic representation of P. falciparum SERA (Pang eta/., 1999) 
SERA contains genes that play important roles in the blood stage. The genes 
are in a cluster of 8 homologues in Chromosome 2 and a ninth one in Chromosome 9 
(Figure 3). Whereas all the SERA proteins are predicted to possess a central domain 
with strong homology with the papain family of cysteine proteases, some, including 
SERA itself, were found to contain a highly unusual cysteine to serine substitution in 
the active site position (Eakin et a/. , 1989; Higgins et a/. , 1989). All SERA 
homologues encode a centrally located "papain-like" protease domain, although in 
SERA 1-SERA5 and in SERA9 the active site cysteine residue is present as a serine 
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(Miller eta!., 2002). The conserved genes in the central region of Chromosome 2 are 
believed to be responsible for the maintenance of blood cycle. 
Monoclonal and polyclonal antibodies raised against SERA inhibit parasite 
growth and a major parasite-inhibitory epitope has been recently mapped to its 47 
kDa N-terminal domain (Fox et a!., 2002) . As a result, dispersion of merozoites is 
inhibited and parasite multiplication does not take place. 
Partial protection may be induced by immunizing Saimiri and Aotus monkeys 
with different fractions of SERA (Perrin eta!., 1984; lnselburg eta!., 1991) including 
the 47 kDa N-terminal domain (Sugiyama et a!., 1996). Therefore, SERA is one of 
malaria antigens that have been proven to induce a certain degree of immunity. 
Chr2 tel ============================~-~=-~====~-~===> tel 
I I 
---
--- SERA locus (- 35 kb) 
I 1 2 3 4 5 6 7 81 
looc::==J-- -~- +DliC:=::J- - -~--- -tooc::=:J- - -1-CJ!Jc::=:J- - - tCJOC:::::::}-- -IOOc::JO 
Ser Ser Ser Ser Ser Cys Cys Cys 
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Chr 9 -- -- -lonc::=::=J- --
Ser 
2 kb 
t-----1 
Figure 3: SERA genes in a cluster of 8 homologues in chromosome 2 and a ninth 
one in chromosome 9 (Miller eta!., 2002) 
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REVIEW OF LITERATURE 
Safitri eta/. (2002) reported the sequence diversity in exon II of SERA gene. Exon II 
comprises two repetitive domains and the variation in exon II is essentially dimorphic. 
All known alleles may be grouped into two basic types, named FCR3 and K1 
(Morimatsu et a/., 1997). A third type, Honduras1 , was the product of homologous 
recombination between FCR3-type and K1-type alleles (Liu eta/. , 2000). 
The patterns of sequence va riation in SR are reminiscent of those found in the 
repeat arrays in the central region of the circumsporozoite protein (CSP) of 
Plasmodium falciparum . Two major mechanism may generate new SERA alleles; 
one is insertion or deletion of repeat units and the second mechanism is homologues 
recombinant between alleles of different dimorphic families. 
Miller et a/. (2002) reported that in SERA, the fifth genes in a cluster of eight 
homologues in chromosome 2 and a ninth homologue in chromosome 9 are essential 
to blood stage growth. In chromosome 2, genes at both ends were dispensable 
whereas those in central region could not be disrupted. This implies that they are 
consistent with dominant expression and play the role in maintenance of erythrocytic 
cycle. 
SERA processing is dependent on schizont rupture and at least three proteases (Li 
et a/., 2002) . SERA processing was mediated by trans-proteases from the parasite 
itself and not due to autocatalytic activity. The proteases are membrane associated, 
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correlating with the secretion and accumulation of SERA within the parasitophorous 
vacuole membrane (PVM). Schizont rupture and merozoite release can be inhibited 
by serine protease inhibitor, OFP (responsible for inhibiting cleavage of SERA to P47 
and P73). Cysteine protease inhibitors E-64, leupeptin and iodoacetoamide (each 
inhibiting conversion of P56 to P50) also play a role. 
Following studies on roles of proteases in processing of SERA, Li et a/. (2002) 
studied the localization of its processed fragments. The processing took place in the 
erythrocytes just before schizont ruptures. Cleavage in between the N-terminal and 
central domain takes place first. SE47 is further processed into 2 fragments and the 
cleavage site is located near the centre of the amino acid sequence depending on 
the allelic site. 
Sugiyama et a/. (1996) showed that antisera against SE47 and another epitope 
SE50A inhibited malaria parasite growth. Anti-SE47 serum was more inhibitory than 
anti-SE50A. This suggests that the N-terminal domain of SERA is more accessible 
than the central domain to the antibodies or the binding of the antibodies is more 
toxic to the parasite than the binding to the central domain. 
Puentes et at. (2000) reported that SERA peptides bind specifically to red blood cells. 
Seven peptides with high erythrocyte binding activity were found from a total of 49 
non-overlapping 20-residue-long peptides encompassing the whole SERA protein of 
the FCR3 strain. Six of the seven high binding peptides were found in protein 
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conserved regions including in the SE47. Conserved peptides 6725, 6733 and the 
polymorphic peptide 6727 were found in the 47-kDa fragment (Figure 4). Since 
Puentes published the paper, many researchers have carried out research on the 
high binding peptides. 
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48 kDa 
50 kDa 
~ 18 kDa 
Figure 4: Erythrocyte binding assays using SERA peptides (Puentes eta/., 2000) 
II 
LACUNA IN THE LITERATURE 
From the 49 non-overlapping 20-residue-long peptides encompassing the whole of 
SERA protein of the P. falciparum FCR3 strain, it is found that each peptide from 
6723-6728 has specific binding activity with 2 of the peptides being classified as high 
binding peptides. 
A 22-kDa DNA fragment (SE22) encodes peptides spanning the 6723 -6728 
region (Puentes et a/., 2000). Puentes et a/. (2000) has shown that considering the 
high-binding peptides are very hydrophilic, there is a high possibility that these 
peptides are exposed on SERA surfaces and that it may induce strong antibody 
responses which can inhibit merozoite invasion and contribute towards antimalarial 
immunity. 
The importance of recognizing SERA protein fragments, which binds 
specifically to erythrocyte membranes, implies a possible role for protein or fragments 
cleaved from it in interactions with the erythrocyte membrane in schizont rupture, 
merozoite liberation and merozoite reinvasion of erythrocytes. 
So far, there have been no studies on the 22-kDa DNA fragment (SE22) 
encoding peptides spanning the 6723 -6728 region in the effort to create a vaccine 
for malaria. 
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OBJECTIVE OF THE STUDY 
The aim of this project is to express a synthetic DNA fragment of the SE22 epitope of 
P. faciparum in the expression vector, pPROEX™HTa. The fusion protein produced 
will be isolated and used to immunize rabbits to produce specific antibodies against 
the antigen in a future project. The antibody produced will subsequently be used to 
detect the expression of a synthetic SE22 gene to be cloned into Mycobacterium 
bovis bacille Calmette Guerin. 
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MATERIALS AND METHODS 
Materials 
1. Reagents, chemicals and kits 
All the reagents, chemicals and kits used are tabulated below (Table 1 ). 
Table 1: Reagents, chemicals and kits 
No Reagents, chemicals and kits 
1. QIAprep Spin Miniprep kit, 
QIA quick gel extraction, 
QIA quick PCR purification kit, 
QIAexpressionist kit. 
2. Restriction enzymes (Eco RI, Eco RV, Xba I) 
and buffer, Buffer y+ Tango 2X, 1 OObp marker, 
A. Hind III solution, A. Hind III fragments, Protein 
molecular weight marker. 
3. PCR solution (1 ox buffer, Taq polymerase, 
dNTPs), T 4 ligase and buffer. 
4. PPROEX™HTa, Phosphate Buffer Saline. 
5. Tris base, Ethidium bromide, 0.5 Ethylene-
diamine tetraacetate pH 8.0, Orange G, 
amplicilin, kanamycin, 4-chloro-1-napthol, 
Ponceau S. 
6. Agarose. 
7. Tryptone, yeast extract. 
Supplier 
Qiagen, USA 
Fermentas, USA 
Roche, Germany 
Invitrogen, USA 
Sigma, USA 
Promega, USA 
Pronadisa, Madrid 
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8. Agar base, acetic glacial acid, sodium 
hydroxide, Tween-20, J3-mercaptoethanol, 
hydrogen peroxide. 
9. Sodium chloride, ammonium persulfate, 
TEMED. 
1 0. Sucrose. 
11. Coomasie blue, N,N methylene-bis-acrylamide, 
Sodium-dodecyl-sulphate, 0. 8°/oBis-acrylamide. 
12. Glysine. 
13. Glycerol. 
14. Di-sodium hydrogen orthophosphate 
anhydrous, Sodium di-hydrogen 
orthophosphate. 
15. Anti-6xHis monoclonal antibody. 
16. Nitrocellulose filter Hybond membrane. 
17. Filter membrane (0.2J.tm). 
Merck, Germany 
Gibco-BRL, USA 
Univar, England 
Bio-Rad, USA 
Amresco, USA 
JT Baker, USA 
BDH, England 
Boehringer Mannheim, 
Germany 
Amersham, USA 
Schleicher & Schuell, 
Germany 
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2. Equipment 
Equipment used is tabulated below (Table 2). 
Table 2: Equipment 
No. Equipment Supplier 
1. I nnova 4080 Rotary Shaker New Brunswick Scientific 
Co. Inc., USA 
2. Labconco Purifier Class II Safety Cabinet Labconco Corp., USA 
3. Cyberscan 1 000 pH Meter Eutech, UK 
4. Macrovue UV-25 Hoefer UV Transilluminator, Amersham Pharmacia 
Electrophoresis power supply Biotechnology, USA 
5. Chemi System UVP Bioimaging Systems Ultra Violet Products Ltd., 
Image Analyser USA 
6. Gene Amp PCR System 9700 Thermal Cycler Applied Biosystems, USA 
7. Lambda EZ150 Spectrophotometer Perkinelmer Life and 
Analytical Sciences, USA 
8. Eppendorf Fixed Angle Rotor Microcentrifuge, Eppendorf AG, Germany 
Pipettes 
9. TBVX Hexomix Water Bath Heto-High Technology of 
Scandinavia 
10. Agarose Gel Apparatus CBS Scientific Co., USA 
12. Trans-blot semi-dry transfer cell, Power pac, Bio-Rad Laboratories, USA. 
Mini-protean 3 cell eletrophoresis system. 
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Methods 
1.0 Preparation of reagents and media 
1.1 Sodium hydroxide (NaOH) 1M 
A 1M NaOH was prepared by dissolving 12g of NaOH into 300m I deionised distilled 
H20. The solution was autoclaved at 121 °C for 15 minutes and stored at room 
temperature. 
1.2 Sodium chloride (NaCI) 1M 
A 1M NaCI was prepared by adding 29.2g of NaCI into 500ml deionised distilled H20. 
The solution was autoclaved at 121 °C for 15 minutes and stored at room 
temperature. 
1.3 Hydrogen chloride (HCI) 1M 
A 1M HCI was prepared by adding 8.28ml of HCI stock solution into 91. 72ml 
deionised distilled H20. The solution was stored at room temperature. 
1.4 Luria-Bertani agar (LB agar) 
LB agar was prepared by dissolving 15g of tryptone, 5g of yeast extract, 1 Og of NaCI 
and 15g of agar into 750ml of deionised distilled H20. The pH was adjusted to 7.2 
with 1M NaOH. Deionised distilled H20 was added to make the final volume of 
1000ml. The media was autoclaved at 121°C for 15 minutes. The media was cooled 
down before appropriate antibiotic was added. The agar was stored in the cold room. 
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1.5 Luria-Bertani broth (LB broth} 
LB broth was prepared by dissolving 15g of tryptone, 5g of yeast extract and 1 Og of 
NaCI into 750ml of deionised distilled H20. The pH was adjusted to 7.2 with 1M 
NaOH. Deionised distilled H20 was added to make the final volume of 1 OOOml. The 
media was left to cool before being aliquoted into universal bottles. The media was 
autoclaved at 121 °C for 15 minutes and stored at room temperature. 
1.6 Ampicilin stock solution (50mg/ml} 
Ampicilin stock was prepared by adding 500mg of ampicilin into 1Om I deionised 
distilled H20 to a final concentration of 50mg/ml. The mixture was filtered using 
0.2J.tm filter membrane prior to use and aliquoted (1 ml} into microcentrifuge tubes. 
The antibiotic was stored at -20°C. 
1. 7 Kanamycin stock solution (1 Omg/ml} 
Kanamycin stock was prepared by adding 1 Omg of kanamycin sulfate into 1Om I 
deionised distilled H20. The mixture was filtered using 0.2J.Lm filter membrane prior to 
use and aliquoted (1 ml) into microcentrifuge tubes. The antibiotic was stored at -
20°C. 
1.8 Ethylene-diamine tetraacetate (EDTA) 0.5M 
A 0.5M EDTA solution was prepared by dissolving 93.06g EDTA in 300ml sterile 
deionised distilled H20 while adjusting the pH to 8.0 using 1M NaOH. The solution 
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was made up to 500ml with deionised distilled H20. The 0.5M EDTA solution was 
stored at room temperature. 
1.9 Tris Acetate EDTA (TAE) SOX 
A SOX stock solution of TAE was prepared by dissolving 121 g of Tris base in 
deionised distilled H20 and adding 50ml of 0.5M EDTA and 28.5ml glacial acetic 
acid. Deionised distilled H20 was added to make a final volume of 500ml and stored 
at room temperature. A working solution (1 X TAE) was prepared by diluting 20m I of 
stock solution with 980ml deionised distilled H20. 
1.1 0 Stock solution of ethidium bromide (1 Omg/ml) 
This was prepared by dissolving 1 g of ethidium bromide in 1 OOml de ionised distilled 
H20. The solution was stored in dark bottle at room temperature. 
1.11 Loading buffer 
Loading buffer was prepared by adding 20g of sucrose and 0.2Sg of Orange-G dye 
into a microcentrifuge tube containing 30J.LI of deionised distilled H20. After mixing, 
the volume was added to SOJ.LI deionised distilled H20 and stored at 4°C. 
1.12 Molecular size marker (1 OObp) (50ng/J.LI) 
Molecular size marker (1 OObp) was by adding 20J.LI of stock preparation (2S0ng/J.LI) 
(Fermentas, USA), 20J.LI of 1 X TAE and 60J.LI of Orange-G dye in a microcentrifuge 
tube. The marker was stored at 4°C. 
19 
1.13 Lambda Hind III marker (50ng/Jll) 
Lambda Hind III marker was prepared by adding 20Jll of stock preparation (250ng/Jll) 
(Fermentas, USA), 20J!I of 1X TAE and 60J!I of Orange-G dye in a microcentrifuge 
tube. The marker was stored at 4°C. 
1.14 Magnesium chloride (MgCI2) 1 OOmM 
A 1 OOmM MgCI2 solution was prepared by dissolving 2.033g of MgCI2 in 70ml 
deionised distilled H20. The solution was made up to 1 OOml with deionised distilled 
H20. The solution was autoclaved at 121°C for 15 minutes and stored at room 
temperature. 
1.15 Calcium chloride (CaCI2) 1 OOmM 
A 100mM CaCI2 solution was prepared by dissolving 1.470g of CaCI2 in 70ml 
deionised distilled H20. The solution was made up to 1 OOml with deionised distilled 
H20. The solution was autoclaved at 121°C for 15 minutes and stored at room 
temperature. 
1.16 Glycerol solution (80o/o) 
A 80°/o glycerol solution was prepared by adding 80ml of 1 00°/o glycerol into 20m I 
deionised distilled H20. The solution was autoclaved at 121°C for 15 minutes and 
stored at room temperature. 
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1.17 E. coli Competent cells 
One colony of E. coli was selected and cultured overnight in 1Om I of LB broth. Six 
hundred J.tl of the LB broth was aliquoted into a conical flask containing 60ml LB 
broth. The culture was incubated at 37°C with vigorous shaking until the optical 
density at 600nm wavelength (OD60o) was 0.3. The tube was then centrifuged at 
3000g for 10 minutes at 4°C. The supernatant was discarded and pellet was 
resuspended in 6ml cold 1 OmM MgCI2. The tube was then placed on ice for 45 
minutes. The tube was recentrifuged at 3000g for 1 0 minutes at 4°C and supernatant 
discarded. The pellet was finally resuspended in 400J.tl of cold 1 OmM CaCI2. Sixty J.tl 
of cold 80o/o glycerol was then mixed into the cell suspension which were then 
aliquoted (30J.tl) into microcentrifuge tubes. The tubes were snap-frozen in ice-cold 
ethanol and stored at -80°C. 
1.18 lsopropyi-P-D-thiogalactosidase (IPTG) 1M 
A 1M IPTG stock was prepared by adding 2.38g of IPTG into 1 OOml of deionised 
distilled H20 to a final concentration of 238mg/ml. The mixture was filtered and 
aliquoted (1 ml) into microcentrifuge tubes and stored at -20°C. 
1.19 Stacking gel buffer 
Stacking gel buffer was prepared by dissolving 6.05g of Tris base and 0.4g of 
sodium-dodecyl-sulphate (SDS) into 40ml of deionised distilled H20. The pH was 
adjusted to 6.8 with 1M HCI. Deionised distilled H20 was added to make the final 
volume of 1 OOml. The solution was filtered and stored at 4°C. 
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1.20 Resolving gel buffer 
Resolving gel buffer was prepared by dissolving 90.85g of Tris base and 2g of SDS 
into 40ml of de ionised distilled H20. The pH was adjusted to 9.3 with 1M HCI. 
Deionised distilled H20 was added to make the final volume of 500ml. The solution 
was filtered and stored at 4°C. 
1.21 Protein loading sample buffer 
Protein loading sample buffer was prepared by dissolving 0. 76g of Tris base, 1 g of 
SDS and 1Om I of glycerol into 40ml of de ionised distilled H20. The pH was adjusted 
to 6.8 with 1M HCI. Deionised distilled H20 was added to make the final volume of 
50ml. The solution was filtered and stored at 4°C. 
1.22 Ammonium persulfate (20°/o) 
A 20°/o ammonium persulfate solution was prepared by dissolving 0.1 g ammonium 
persulfate in 500J.tl deionised distilled H20. 
1.23 Protein running buffer 
Protein running buffer was prepared by dissolving 3g of Tris base and 1 g of SDS into 
900ml of deionised distilled H20. The pH was adjusted to 8.3 with 1M HCI. Deionised 
distilled H20 was added to make the final volume of 1 OOOml. The solution was stored 
at 4°C. 
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1.24 Protein transfer buffer 
Protein transfer buffer was prepared by dissolving 3.03g of Tris base, 14.4g of 
glysine and 200ml of methanol into 900ml of deionised distilled H20. Deionised 
distilled H20 was added to make the final volume of 1 OOOml. The solution was stored 
at 4°C. 
1.25 Coomassie Blue solution 
Coomassie Blue solution was prepared by dissolving O.Bg of Coomassie Blue and 
1 OOml of isopropyl solution into 50ml of sterilized deionised distilled H20. Deionised 
distilled H20 was added to make the final volume of 200ml and stored at room 
temperature. A 1 0°/o acetic acid was added prior to use. 
1.26 Ponceau S solution 
Ponceau S solution was prepared by dissolving 0.5g of Ponceau S in 1 ml of acetic 
acid. Deionised distilled H20 was added to make a final volume of 100ml and stored 
at room temperature. 
1.27 Skimmed milk solution 3°/o(vN) 
Skimmed milk solution was prepared by dissolving 3g of skimmed milk powder into 
50ml of sterilized deionised distilled H20. Deionised distilled H20 was added to make 
the final volume of 1 OOml to give a 3%> (v/v) solution. 
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1.28 Phosphate buffered saline (PBS) 
Phosphate buffered saline (PBS) was prepared by dissolving 11.5g of Di-sodium 
hydrogen orthophosphate anhydrous, 2.96g of sodium di-hydrogen orthophosphate 
and 5.84g NaCI into 900ml of deionised distilled H20. The pH was adjusted to 7.5 
with 1M HCI. De ionised distilled H20 was added to make the final volume of 1 OOOml. 
The solution was stored at 4°C. 
1.29 PBS-Tween 20 (PBS-T20) 
PBS-Tween 20 (PBS-T20) was prepared by adding SOOJ.LI of Tween-20 into 999.5ml 
of PBS to give a 0.1% (v/v) solution. The solution was stored at 4°C. 
1.30 Chromogenic substrate (4-chloro-1-napthol and hydrogen peroxide) solution 
Reagent A was prepared by dissolving 0.3g of 4-chloro-1-napthol into 100ml of cold 
methanol. Reagent 8 was prepared by mixing 300ml of hydrogen peroxide with 
SOOml of PBS. Both reagents were stored at 4°C. 
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